Facial Paralysis Sequel Treatment with Botulinum Toxin and Fillers

norosirurjiozel12-1-22kapak

Hasan Ahmet ÖZDOĞANa , Begüm Bahar YILMAZb, Gamze ÇİFTÇİa
aİstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Otorhinolaryngology, İstanbul, Türkiye
bİstanbul Başakşehir Çam and Sakura City Hospital, Department of Otorhinolaryngology, İstanbul, Türkiye

Özdoğan HA, Yılmaz BB, Çiftçi G. Facial paralysis sequel treatment with Botulinum toxin and fillers. In: Sanus GZ, Batıoğlu Karaaltın A, eds. Surgical Management of Facial Nerve Paralysis. 1st ed. Ankara: Türkiye Klinikleri; 2022. p.238-43.

Article Language: EN

ABSTRACT
Botulinum toxin (BTX) and dermal fillers are commonly used methods to treat facial lines on the face. Botulinum toxin injections and dermal fillers are recently used for facial paralysis complications management. Thirty percent of the facial paralysis cases including Bell’s palsy can have incomplete aesthetic or functional recovery. Patients end up with facial asymmetry, facial synkinesis or with misrouted recovery they could end up having hyperlacrimation, gustatory sweating. Botulinum toxin and dermal fillers are increasingly used in the management of facial palsy. In this section, it is aimed to mention the use of botulinum toxin and dermal fillers in the treatment of facial paralysis.

Keywords: Facial paralysis; botulinum toxin; filler injection; facial nerve

Referanslar

  1. Filipo r, Spahiu I, Covelli e, Nicastri M, Bertoli GA. Botulinum toxin in the treatment of facial synkinesis and hyperkinesis. Laryngoscope. 2012;122(2):266-70. [Crossref]  [PubMed]
  2. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology. 2006;67(10):1855-6. [Crossref]  [PubMed]
  3. Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22(1):34-9. [Crossref]  [PubMed]
  4. Small r. Botulinum toxin injection for facial wrinkles. Am Fam Physician. 2014;90(3):168-75.
  5. Crowner Be, Torres-russotto D, Carter Ar, racette BA. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol. 2010;33(5):243-7. [Crossref]  [PubMed]  [PMC]
  6. Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;147:84-8. [Crossref]  [PubMed]
  7. Cooper L, Lui M, Nduka C. Botulinum toxin treatment for facial palsy: a systematic review. J Plast reconstr Aesthet Surg. 2017;70(6):833-41. [Crossref]  [PubMed]
  8. Boroojerdi B, Ferbert A, Schwarz M, Herath H, Noth J. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998;65(1):111-4. [Crossref]  [PubMed]  [PMC]
  9. Yamamoto e, Nishimura H, Hirono Y. Occurrence of sequelae in Bell's palsy. Acta Otolaryngol Suppl. 1988;446:93-6. [Crossref]
  10. Moran CJ, Neely JG. Patterns of facial nerve synkinesis. Laryngoscope. 1996;106(12 Pt 1):1491-6. [Crossref]  [PubMed]
  11. Malhotra A. Marin-Amat syndrome: a case of acquired facial synkinesis. BMJ Case rep. 2013;2013:bcr2013010030. [Crossref]  [PubMed]  [PMC]
  12. Mcelhinny er, reich I, Burt B, Mancini r, Wladis eJ, Durairaj VD, et al. Treatment of pseudoptosis secondary to aberrant regeneration of the facial nerve with botulinum toxin type A. Ophthalmic Plast reconstr Surg. 2013;29(3):175-8. [Crossref]  [PubMed]
  13. Beurskens CH, Heymans PG. Mime therapy improves facial symmetry in people with long-term facial nerve paresis: a randomised controlled trial. Aust J Physiother. 2006;52(3):177-83. [Crossref]  [PubMed]
  14. Brach JS, VanSwearingen JM, Lenert J, Johnson PC. Facial neuromuscular retraining for oral synkinesis. Plast reconstr Surg. 1997;99(7):1922-31; discussion 1932-3. [Crossref]  [PubMed]
  15. Nakamura K, Toda N, Sakamaki K, Kashima K, Takeda N. Biofeedback rehabilitation for prevention of synkinesis after facial palsy. Otolaryngol Head Neck Surg. 2003;128(4):539-43. [Crossref]
  16. Roggenkämper P, Laskawi r, Damenz W, Schröder M, Nüssgens Z. [Involuntary lid closure caused by defective healing of facial paralysis and its treatment with botulinum toxin]. Klin Monbl Augenheilkd. 1991;198(4):268-70. German. [Crossref]  [PubMed]
  17. Wittekindt C. Adjuvant treatment with botulinum toxin and fillers. In: Guntinas-Lichius O, Schaitkin BM, eds. Facial Nerve Disorders and Diseases: Diagnosis and Management. 1st ed. Stuttgart: Thieme; 2016. p.329-41.
  18. Armstrong MW, Mountain re, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol Allied Sci. 1996;21(1):15-20. [Crossref]  [PubMed]
  19. Montoya FJ, riddell Ce, Caesar r, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. eye (Lond). 2002;16(6):705-9. [Crossref]  [PubMed]
  20. Vartanian AJ, Dayan SH. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am. 2005;13(1):1-10. [Crossref]  [PubMed]
  21. Keegan DJ, Geerling G, Lee JP, Blake G, Collin Jr, Plant GT. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol. 2002;86(1):43-6. [Crossref]  [PubMed]  [PMC]
  22. Nava-Castañeda A, Tovilla-Canales JL, Boullosa V, Tovilla-y-Pomar JL, Monroy-Serrano MH, Tapia-Guerra V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthalmic Plast reconstr Surg. 2006;22(6):453-6. [Crossref]  [PubMed]
  23. Moltrecht M, Michel O. The woman behind Frey's syndrome: the tragic life of Lucja Frey. Laryngoscope. 2004;114(12):2205-9. [Crossref]  [PubMed]
  24. Guntinas-Lichius O. Increased botulinum toxin type A dosage is more effective in patients with Frey's syndrome. Laryngoscope. 2002;112(4):746-9. [Crossref]  [PubMed]
  25. Motz KM, Kim YJ. Auriculotemporal syndrome (Frey syndrome). Otolaryngol Clin North Am. 2016;49(2):501-9. [Crossref]  [PubMed]  [PMC]
  26. Torretta S, Pignataro L, Capaccio P, Brevi A, Mazzola r. Fat injections for the management of post-parotidectomy Frey syndrome: a technical note. J Craniomaxillofac Surg. 2012;40(2):173-6. [Crossref]  [PubMed]
  27. Choi J, Park SI, rha eY, Seo BF, Kwon H, Jung SN. Acellular dermal matrix (Insuregraf) in the prevention of Frey's syndrome and surgical site depression after parotidectomy. Arch Craniofac Surg. 2019;20(3):176-80. [Crossref]  [PubMed]  [PMC]
  28. Aizawa T, Kuwabara M, Kubo S, Aoki S, Azuma r, Kiyosawa T. Polyglycolic acid felt for prevention of Frey syndrome after parotidectomy. Ann Plast Surg. 2018;81(4):438-40. [Crossref]  [PubMed]
  29. Ghassemi A, Modabber A, Brzoska PO, Sababi M. Vascularised fatty tissue: its role in prevention of the symptoms of Frey syndrome after parotidectomy. Br J Oral Maxillofac Surg. 2018;56(9):877-80. [Crossref]  [PubMed]
  30. de Maio M, Bento rF. Botulinum toxin in facial palsy: an effective treatment for contralateral hyperkinesis. Plast reconstr Surg. 2007;120(4):917-27. [Crossref]  [PubMed]
  31. Kim J. Contralateral botulinum toxin injection to improve facial asymmetry after acute facial paralysis. Otol Neurotol. 2013;34(2):319-24. [Crossref]  [PubMed]
  32. Salles AG, Toledo PN, Ferreira MC. Botulinum toxin injection in longstanding facial paralysis patients: improvement of facial symmetry observed up to 6 months. Aesthetic Plast Surg. 2009;33(4):582-90. [Crossref]  [PubMed]
  33. Sadjadpour K. Postfacial palsy phenomena: faulty nerve regeneration or ephaptic transmission? Brain res. 1975;95(2-3):403-6. [Crossref]  [PubMed]
  34. Alam M, Dover JS. Management of complications and sequelae with temporary injectable fillers. Plast reconstr Surg. 2007;120(6 Suppl):98S105S. [Crossref]  [PubMed]
  35. Kablik J, Monheit GD, Yu L, Chang G, Gershkovich J. Comparative physical properties of hyaluronic acid dermal fillers. Dermatol Surg. 2009;35 Suppl 1:302-12. [Crossref]  [PubMed]
  36. Sklar JA, White SM. radiance FN: a new soft tissue filler. Dermatol Surg. 2004;30(5):764-8; discussion 768. [Crossref]  [PubMed]
  37. Breiting V, Aasted A, Jørgensen A, Opitz P, rosetzsky A. A study on patients treated with polyacrylamide hydrogel injection for facial corrections. Aesthetic Plast Surg. 2004;28(1):45-53. [Crossref]  [PubMed]
  38. Karim rB, Hage JJ, van rozelaar L, Lange CA, raaijmakers J. Complications of polyalkylimide 4% injections (Bio-Alcamid): a report of 18 cases. J Plast reconstr Aesthet Surg. 2006;59(12):1409-14. [Crossref]  [PubMed]
  39. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005;31(8 Pt 1):893-7. erratum in: Dermatol Surg. 2008;34(1):135. [Crossref]  [PubMed]
  40. Carle MV, roe r, Novack r, Boyer DS. Cosmetic facial fillers and severe vision loss. JAMA Ophthalmol. 2014;132(5):637-9. [Crossref]  [PubMed]
  41. Buck DW 2nd, Alam M, Kim JY. Injectable fillers for facial rejuvenation: a review. J Plast reconstr Aesthet Surg. 2009;62(1):11-8. [Crossref]  [PubMed]